The companies have identified an initial set of genetic biomarkers to predict drug response and will validate the findings in ...
The Shenzhen, China-based biotech plans to launch a Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026.
BobcatBio brought on the contract development and manufacturing organization to support manufacturing for ongoing Phase I studies in lymphoma and solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results